Business
Novavax vaccine shows 89.7% efficacy against Covid, UK clinical trial results show – ThePrint
Phase 3 trials of Novavax vaccine, published in UK, reports no cases of hospitalisation among participants who received both…
New Delhi: American biotechnology company Novavax’s two-dose vaccine can confer 89.7 per cent protection against the SARS-CoV-2 infection, according to phase 3 trial results published in the UK Thursday. The vaccine also showed high efficacy against Alpha…
Continue Reading
